- Home
- IRT vs GH Comparison
IRT vs GH Comparison
Compare IRT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRT
- GH
- Stock Information
- Founded
- IRT 2009
- GH 2011
- Country
- IRT United States
- GH United States
- Employees
- IRT N/A
- GH N/A
- Industry
- IRT Real Estate Investment Trusts
- GH Medical Specialities
- Sector
- IRT Real Estate
- GH Health Care
- Exchange
- IRT Nasdaq
- GH Nasdaq
- Market Cap
- IRT 4.2B
- GH 4.3B
- IPO Year
- IRT 2013
- GH 2018
- Fundamental
- Price
- IRT $18.80
- GH $37.46
- Analyst Decision
- IRT Buy
- GH Strong Buy
- Analyst Count
- IRT 9
- GH 14
- Target Price
- IRT $20.33
- GH $39.93
- AVG Volume (30 Days)
- IRT 1.8M
- GH 1.8M
- Earning Date
- IRT 02-12-2025
- GH 02-20-2025
- Dividend Yield
- IRT 3.38%
- GH N/A
- EPS Growth
- IRT N/A
- GH N/A
- EPS
- IRT N/A
- GH N/A
- Revenue
- IRT $641,630,000.00
- GH $692,256,000.00
- Revenue This Year
- IRT N/A
- GH $32.21
- Revenue Next Year
- IRT $4.97
- GH $16.90
- P/E Ratio
- IRT N/A
- GH N/A
- Revenue Growth
- IRT N/A
- GH 29.20
- 52 Week Low
- IRT $14.08
- GH $15.81
- 52 Week High
- IRT $22.26
- GH $39.29
- Technical
- Relative Strength Index (RSI)
- IRT 34.14
- GH 66.67
- Support Level
- IRT $18.12
- GH $34.80
- Resistance Level
- IRT $19.96
- GH $37.46
- Average True Range (ATR)
- IRT 0.38
- GH 1.78
- MACD
- IRT -0.14
- GH 0.51
- Stochastic Oscillator
- IRT 28.69
- GH 80.49
About IRT Independence Realty Trust Inc.
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.